Navigation Links
Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ 37 Million
Date:2/14/2008

Three-Year Extension for Integrated Drug Discovery Support in the Search of

Novel Drug Candidates for the Treatment of Huntington Disease

HAMBURG, Germany, OXFORD, England and LOS ANGELES, California, February 14 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) today announced that CHDI Foundation, Inc., a not-for-profit organization pursuing a biotech approach to finding therapies for Huntington Disease (HD), has extended its collaboration with Evotec to the end of 2010 to help them advance their Huntington's Disease drug discovery programs. This contract extension is worth up to US$ 37 million in research payments for Evotec.

The collaboration covers Evotec's entire drug discovery offering, including its expertise in medicinal chemistry, biology and compound sourcing. Specifically, this includes biochemical and cellular assay development and high content screening on interesting cell lines with the aim of identifying novel starting points for medicinal chemistry programs. In addition, Evotec supplies key support in the area of medicinal chemistry and supporting biology optimization on multiple biological targets that are of high importance for the treatment of HD. Using skills in computational chemistry, structural biology and protein crystallography, Evotec characterizes active compounds further and optimizes their potency and selectivity to generate lead molecules for subsequent progression into clinical trials.

Evotec and CHDI have worked together since March 2006. During this time, the collaborative relationship has grown significantly. In addition to the contract extension announced today, the companies also have an agreement whereby Evotec provides ultra-high-throughput screening (uHTS) support.

"This is an important collaboration for CHDI. As collaborative enablers, CHDI depends on a network of academic and industrial partners to conduct its research efforts. Based on 18 months of working together s
'/>"/>

SOURCE Evotec AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
2. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
3. Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York
4. Evotec AG: R&D Update on 16 October 2007 Live on the Internet
5. Evotec Reports Third Quarter 2007 Results
6. Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board
7. Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
8. Evotec to Present at the BIO CEO & Investor Conference 2008 in New York
9. Roche Extends Tender Offer for Ventana
10. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
11. NASA Extends Cooperative Agreement With NSBRI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Miles Holder, formerly of Micron Research and ... team as Sales/Marketing Manager. Mr. Holder has over 25 ... the graphite industry. , “We are thrilled to be ... Trinkley, VP of Market and Product Development for Graphel ... the graphite industry, along with his proven track record ...
(Date:11/26/2014)... DE (PRWEB) November 26, 2014 ... Heroes recognition reception on December 5, 2014, in San ... meeting. The MPN Heroes event will honor clinicians, caregivers, ... field of myeloproliferative neoplasms (MPNs). , Special guest ... discuss his family's cancer journey at the reception. ...
(Date:11/26/2014)... 25 novembre 2014 Theravalues Corporation est fier ... marché européen au salon Hi Europe 2014 (du ... ). Curcumine la plus biodisponible actuellement ... (non-cristalline) à des ingrédients approuvés par les règlements ... jaune présent dans la racine de curcuma ( ...
(Date:11/26/2014)... /PRNewswrie/ -- Theravalues Corporation annuncia con orgoglio il lancio ... di Hi Europe 2014 (dal 2 al 4 dicembre, ... della curcumina con la maggiore biodisponibilità di sempre, con ... approvati dalle norme europee. La curcumina è ... ( Curcuma longa ) che è stata associata con ...
Breaking Biology Technology:Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3
... Mass., Sept. 6 Boston Scientific,Corporation (NYSE: BSX ... elected Ray Elliott as a Director. Mr. Elliott, ... Inc.,Previously, he served as Chairman, President and Chief Executive ... Zimmer since 1997. Mr. Elliott,has extensive operating and director ...
... Proteon Therapeutics,( http://www.proteontherapeutics.com ), a privately held ... the,medical needs of patients with renal and ... with its current investor syndicate.,Proteon will use ... candidate,PRT-201, into human clinical studies in both ...
... a world leader in,radiation oncology and non-invasive ... radiotherapy, stereotactic radiosurgery and clinical,workflow solutions at ... 2007 meeting in Barcelona, Spain, September 8-13. ... health care,professionals are expected at the Ninth ...
Cached Biology Technology:Boston Scientific Announces Election of Ray Elliott to Its Board of Directors 2Boston Scientific Announces Election of Ray Elliott to Its Board of Directors 3Proteon Therapeutics Completes $12 Million Financing and Hires CFO 2Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability 2Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability 3
(Date:11/4/2014)... (Philadelphia, PA) – Temple University School of Medicine ... Explorations winner, an initiative funded by the Bill ... MPH, Professor of Obstetrics, Gynecology and Reproductive Sciences; ... at Temple University School of Medicine will pursue ... titled "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", ...
(Date:11/4/2014)... of Madagascar,s 101 species of lemurs are threatened with ... rainforests they call home. A new study by Rice ... on rainforest tree populations, which raises concerns about the ... rich biodiversity. , A large proportion of trees in ... in turn disperse the seeds of their fruit trees ...
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® , ... life sciences company focused on commercialization of its ... for the treatment of neurological and neuropsychiatric disorders, ... Property has issued a Notice of Allowance for ... is co-owned by NeuroSigma and the Regents of ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... took a global corps of scientists approximately $500 million and ... the human genome. Five years later, Boston College Biologist Gabor ... analyze half a million DNA sequences in 10 minutes. ... new breed of computer programs able to accurately process the ...
... New Rochelle, NY, March 27, 2008 -Sustaining hope in ... amyotrophic lateral sclerosis (ALS) should be a goal of ... continuum from focusing on the self to concern for ... April issue (Volume 8, Number 3) of Journal of ...
... patient lying on an operating table, while another student conducts ... a real OR or treatment room, except that the patients ... theyre robots., These high-tech, electronically outfitted mannequins are equipment in ... at the Johns Hopkins Outpatient Center in East Baltimore that ...
Cached Biology News:Software developed by Boston College lab delivers speed and accuracy to genome research 2Software developed by Boston College lab delivers speed and accuracy to genome research 3Hope among patients with ALS may take a variety of forms 2Actor-robots 'staff' part of new $5M simulation training center 2
... Wellpro 384, compatible ... automated liquid handling system ... quickly and accurately prepares ... dilutions. The Wellpro ...
...
...
Multidrop DW is a high-speed automated dispenser for Deep Well plates, 1.1 ml test tubes and 96-well plates. Designed for accuracy and precision, the Multidrop DW dispenses up to eight different reag...
Biology Products: